The drug hit the market in 2022 as Mounjaro for Type 2 diabetes and in 2023 as Zepbound for obesity. The drug threatened to cannibalize sales of another Lilly diabetes drug called Trulicity, which was racking up big sales. Its diabetes drug Ozempic was already on the market and its main ingredient was being tested for weight loss. Last year, Walmart CEO Doug McMillon told Bloomberg News that shoppers who picked up prescriptions for GLP-1 drugs at Walmart pharmacies were putting less food in their grocery baskets. A potential avenue for relief is to make a GLP-1 drug in pill form.

Source: Wall Street Journal June 14, 2024 11:14 UTC